CA2511496A1 - Cardiotonic compounds with inhibitory activity against .beta.-adrenergic receptors and phosphodiesterase - Google Patents

Cardiotonic compounds with inhibitory activity against .beta.-adrenergic receptors and phosphodiesterase Download PDF

Info

Publication number
CA2511496A1
CA2511496A1 CA002511496A CA2511496A CA2511496A1 CA 2511496 A1 CA2511496 A1 CA 2511496A1 CA 002511496 A CA002511496 A CA 002511496A CA 2511496 A CA2511496 A CA 2511496A CA 2511496 A1 CA2511496 A1 CA 2511496A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
alkyl
compound
compounds
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511496A
Other languages
English (en)
French (fr)
Inventor
Gregory S. Hamilton
Harry Jefferson Leighton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artesian Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2511496A1 publication Critical patent/CA2511496A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002511496A 2002-12-23 2003-12-23 Cardiotonic compounds with inhibitory activity against .beta.-adrenergic receptors and phosphodiesterase Abandoned CA2511496A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43552402P 2002-12-23 2002-12-23
US60/435,524 2002-12-23
PCT/US2003/041031 WO2004058726A2 (en) 2002-12-23 2003-12-23 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
CA2511496A1 true CA2511496A1 (en) 2004-07-15

Family

ID=32682255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511496A Abandoned CA2511496A1 (en) 2002-12-23 2003-12-23 Cardiotonic compounds with inhibitory activity against .beta.-adrenergic receptors and phosphodiesterase

Country Status (7)

Country Link
US (1) US20070117978A1 (https=)
EP (1) EP1575923A2 (https=)
JP (1) JP2006513222A (https=)
AU (1) AU2003300297A1 (https=)
CA (1) CA2511496A1 (https=)
MX (1) MXPA05006975A (https=)
WO (1) WO2004058726A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
JP2008521806A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物
US20080255134A1 (en) * 2004-11-30 2008-10-16 Artesian Therapeutics, Inc. Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
JP2009506123A (ja) 2005-08-29 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
EP1919905B1 (en) 2005-08-29 2011-02-23 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases
WO2007027594A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CN102223882B (zh) * 2008-11-25 2016-02-03 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
EP3021832B9 (en) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CA2930033C (en) 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283382A (en) * 1975-12-27 1977-07-12 Otsuka Pharmaceut Co Ltd Synthesis of carbostyril derivatives
DE2609645A1 (de) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE2644833A1 (de) * 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU565621B2 (en) * 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
DK391189A (da) * 1988-08-10 1990-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2931635B2 (ja) * 1989-06-19 1999-08-09 帝国臓器製薬株式会社 ピリダジノン化合物
NZ234087A (en) * 1989-06-19 1991-08-27 Teikoku Hormone Mfg Co Ltd 2-(3-aryloxy(2-hydroxy-propylamino))-2-methylpropyl- aminophenyl pyridazine derivatives
CA2027863A1 (en) * 1989-11-20 1991-05-21 George Sachs And Jai Moo Shin Partnership Of Michael E. Garst Anti-inflammatory furanone compounds
TW201305B (https=) * 1991-04-03 1993-03-01 Otsuka Pharma Co Ltd
JPH05283382A (ja) * 1992-03-31 1993-10-29 Murata Mfg Co Ltd 半導体ウェハの裏面加工方法及び裏面加工時における半導体ウェハの表面側構造
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5827893A (en) * 1996-03-29 1998-10-27 Lurie; Keith G. Mechanical and pharmacological therapies to treat cardiac arrest
WO1998010765A1 (en) * 1996-09-13 1998-03-19 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
NZ522882A (en) * 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
CZ20031012A3 (en) * 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

Also Published As

Publication number Publication date
JP2006513222A (ja) 2006-04-20
AU2003300297A1 (en) 2004-07-22
WO2004058726A3 (en) 2004-10-28
WO2004058726A2 (en) 2004-07-15
EP1575923A2 (en) 2005-09-21
US20070117978A1 (en) 2007-05-24
MXPA05006975A (es) 2005-12-14

Similar Documents

Publication Publication Date Title
JP7469522B2 (ja) ベンゾチアゾール類誘導体及びその使用
CA2511496A1 (en) Cardiotonic compounds with inhibitory activity against .beta.-adrenergic receptors and phosphodiesterase
US20080255134A1 (en) Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase
US7098211B2 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
HU223945B1 (hu) 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
US20070060748A1 (en) Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
US20080090827A1 (en) Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
FR2685329A1 (fr) Derives de 3(2h)-pyridazinone et procede pour les preparer.
US5646300A (en) (1H-indol-1-yl)-2-(amino)acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
WO2005035505A2 (en) Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
JP2000506874A (ja) 抗喘息性、抗アレルギー性、抗炎症性および免疫調節作用を有する１，３，５―トリ置換されたインダゾール誘導体
AU2004259703A1 (en) Novel compounds
US12465588B2 (en) Indole carboxamide derivative and pharmaceutical composition containing same
US20040077878A1 (en) Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
US20070066619A1 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
KR102114389B1 (ko) 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
CN113651767A (zh) 一种苯并异噁唑类杂环化合物及其制备方法和应用
JPWO2001083429A1 (ja) アニリン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20101223